153 related articles for article (PubMed ID: 18022737)
1. Immunotherapy of prostate cancer in a murine model using a novel GnRH based vaccine candidate.
Junco JA; Peschke P; Zuna I; Ehemann V; Fuentes F; Bover E; Pimentel E; Basulto R; Reyes O; Calzada L; Castro MD; Arteaga N; López Y; Garay H; Hernández H; Bringas R; Guillén GE
Vaccine; 2007 Dec; 25(50):8460-8. PubMed ID: 18022737
[TBL] [Abstract][Full Text] [Related]
2. Very small size proteoliposomes (VSSP) and Montanide combination enhance the humoral immuno response in a GnRH based vaccine directed to prostate cancer.
Aguilar FF; Barranco JJ; Fuentes EB; Aguilera LC; Sáez YL; Santana MD; Vázquez EP; Baker RB; Acosta OR; Pérez HG; Nieto GG
Vaccine; 2012 Oct; 30(46):6595-9. PubMed ID: 22921738
[TBL] [Abstract][Full Text] [Related]
3. Gonadotrophin releasing hormone-based vaccine, an effective candidate for prostate cancer and other hormone-sensitive neoplasms.
Junco JA; Basalto R; Fuentes F; Bover E; Reyes O; Pimentel E; Calzada L; Castro MD; Arteaga N; López Y; Hernández H; Bringas R; Garay H; Peschke P; Bertot J; Guillén G
Adv Exp Med Biol; 2008; 617():581-7. PubMed ID: 18497085
[TBL] [Abstract][Full Text] [Related]
4. Active component of a GnRH based vaccine binds to natural GnRH receptors in Dunning R3327-G cell line and human prostate carcinoma vesicles.
Bover Fuentes E; Fuentes Aguilar F; Junco Barranco J; Zaldivar Merino I; Arteaga Moré N; Calzada Aguilera L; López Sáez Y; Pimentel Vázquez E; Basulto Baker R
J Exp Ther Oncol; 2007; 6(4):279-84. PubMed ID: 18038761
[TBL] [Abstract][Full Text] [Related]
5. Synthetic luteinizing hormone releasing hormone (LHRH) vaccine for effective androgen deprivation and its application to prostate cancer immunotherapy.
Finstad CL; Wang CY; Kowalski J; Zhang M; Li ML; Li XM; Xia WG; Bosland MC; Murthy KK; Walfield AM; Koff WC; Zamb TJ
Vaccine; 2004 Mar; 22(9-10):1300-13. PubMed ID: 15003660
[TBL] [Abstract][Full Text] [Related]
6. Improved efficacy of DNA vaccination against prostate carcinoma by boosting with recombinant protein vaccine and by introduction of a novel adjuvant epitope.
Lu Y; Ouyang K; Fang J; Zhang H; Wu G; Ma Y; Zhang Y; Hu X; Jin L; Cao R; Fan H; Li T; Liu J
Vaccine; 2009 Aug; 27(39):5411-8. PubMed ID: 19616501
[TBL] [Abstract][Full Text] [Related]
7. A recombinant luteinising-hormone-releasing-hormone immunogen bioeffective in causing prostatic atrophy.
Talwar GP; Raina K; Gupta JC; Ray R; Wadhwa S; Ali MM
Vaccine; 2004 Sep; 22(27-28):3713-21. PubMed ID: 15315851
[TBL] [Abstract][Full Text] [Related]
8. Immunization with a recombinant GnRH vaccine conjugated to heat shock protein 65 inhibits tumor growth in orthotopic prostate cancer mouse model.
Xu J; Zhu Z; Wu J; Liu W; Shen X; Zhang Y; Hu Z; Zhu D; Roque RS; Liu J
Cancer Lett; 2008 Feb; 259(2):240-50. PubMed ID: 18039558
[TBL] [Abstract][Full Text] [Related]
9. Effect of active immunization against luteinizing hormone-releasing hormone on the androgen-sensitive Dunning R3327-PAP and androgen-independent Dunning R3327-AT2.1 prostate cancer sublines.
Fuerst J; Fiebiger E; Jungwirth A; Mack D; Talwar PG; Frick J; Rovan E
Prostate; 1997 Jul; 32(2):77-84. PubMed ID: 9215394
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of an anti-fertility vaccine based on mammalian gonadotrophin releasing hormone (GnRH-I)--a histological comparison in male animals.
Ferro VA; Khan MA; McAdam D; Colston A; Aughey E; Mullen AB; Waterston MM; Harvey MJ
Vet Immunol Immunopathol; 2004 Sep; 101(1-2):73-86. PubMed ID: 15261694
[TBL] [Abstract][Full Text] [Related]
11. Anti-GnRH antibodies can induce castrate levels of testosterone in patients with advanced prostate cancer.
Simms MS; Scholfield DP; Jacobs E; Michaeli D; Broome P; Humphreys JE; Bishop MC
Br J Cancer; 2000 Aug; 83(4):443-6. PubMed ID: 10945488
[TBL] [Abstract][Full Text] [Related]
12. Effect of immunisation against gonadotrophin releasing hormone isoforms (mammalian GnRH-I, chicken GnRH-II and lamprey GnRH-III) on murine spermatogenesis.
Khan MA; Prevost M; Waterston MM; Harvey MJ; Ferro VA
Vaccine; 2007 Mar; 25(11):2051-63. PubMed ID: 17240004
[TBL] [Abstract][Full Text] [Related]
13. Longitudinal microSPECt/CT imaging and pharmacokinetics of synthetic luteinizing hormone-releasing hormone (LHRH) vaccine in rats.
Chang CH; Hsu WC; Wang CY; Jan ML; Tsai TH; Lee TW; Lynn SG; Yeh CH; Chang TJ
Anticancer Res; 2007; 27(5A):3251-8. PubMed ID: 17970068
[TBL] [Abstract][Full Text] [Related]
14. A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer.
Chianese-Bullock KA; Irvin WP; Petroni GR; Murphy C; Smolkin M; Olson WC; Coleman E; Boerner SA; Nail CJ; Neese PY; Yuan A; Hogan KT; Slingluff CL
J Immunother; 2008 May; 31(4):420-30. PubMed ID: 18391753
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of two GnRH-I based vaccine formulations on the testes function of entire Suffolk cross ram lambs.
Earl ER; Waterston MM; Aughey E; Harvey MJ; Matschke C; Colston A; Ferro VA
Vaccine; 2006 Apr; 24(16):3172-83. PubMed ID: 16483697
[TBL] [Abstract][Full Text] [Related]
16. Inhibition effects on liver tumors of BALB/c mice bearing H22 cells by immunization with a recombinant immunogen of GnRH linked to heat shock protein 65.
Zhang Y; Xu J; Zhao R; Liu J; Wu J
Vaccine; 2007 Sep; 25(39-40):6911-21. PubMed ID: 17728021
[TBL] [Abstract][Full Text] [Related]
17. Advances in specific immunotherapy for prostate cancer.
Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M
Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335
[TBL] [Abstract][Full Text] [Related]
18. Modifications increasing the efficacy of recombinant vaccines; marked increase in antibody titers with moderately repetitive variants of a therapeutic allergy vaccine.
Johansson J; Hellman L
Vaccine; 2007 Feb; 25(9):1676-82. PubMed ID: 17150285
[TBL] [Abstract][Full Text] [Related]
19. The non-toxic and biodegradable adjuvant Montanide ISA 720/CpG can replace Freund's in a cancer vaccine targeting ED-B--a prerequisite for clinical development.
Huijbers EJ; Femel J; Andersson K; Björkelund H; Hellman L; Olsson AK
Vaccine; 2012 Jan; 30(2):225-30. PubMed ID: 22079080
[TBL] [Abstract][Full Text] [Related]
20. Rapid suppression of plasma testosterone levels and tumor growth in the dunning rat model treated with degarelix, a new gonadotropin-releasing hormone antagonist.
Princivalle M; Broqua P; White R; Meyer J; Mayer G; Elliott L; Bjarnason K; Haigh R; Yea C
J Pharmacol Exp Ther; 2007 Mar; 320(3):1113-8. PubMed ID: 17179469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
